ATOS vs AVTX

Atossa Therapeutics, Inc. vs Avalo Therapeutics, Inc. — Valuation Comparison 2026

ATOS

Pharmaceutical Preparations
Atossa Therapeutics, Inc.
Quality
4.5
out of 10
Value Trap
24
SAFE
Price
$5.23
Last close
Models
7/13
Active
VS

AVTX

Pharmaceutical Preparations
Avalo Therapeutics, Inc.
Quality
4.7
out of 10
Value Trap
49
WARN
Price
$15.95
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType ATOS Fair ValueATOS Upside AVTX Fair ValueAVTX Upside
Bayesian DCF Intrinsic $3.34 -36.1% $4.57 -71.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.52 -90.2% $0.69 -95.7%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ATOS vs AVTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ATOS vs AVTX — Which Stock Is More Undervalued?

AVTX scores higher with a 4.7/10 quality rating vs ATOS's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Atossa Therapeutics, Inc. (ATOS) and Avalo Therapeutics, Inc. (AVTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ATOS currently trades at $5.23 with a QOC of 4.5/10, while AVTX trades at $15.95 with a QOC of 4.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).